Variable clinical presentations of nasal and waldeyer ring natural killer/T-cell lymphoma

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2905-2912

  Li, Ye Xiong ^a   Liu, Qing Feng ^a   Fang, Hui ^a   Qi, Shu Nan ^a   Wang, Hua ^a   Wang, Wei Hu ^a   Song, Yong Wen ^a   Lu, Jiade ^b   Jin, G ^a   Wang, Shu Lian ^a   Liu, Yue Ping ^a   Lu, Ning ^a   Liu, Xin Fan ^a   Yu, Zi Hao ^a  

^a CANCER HOSPITAL   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDEYER RING;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349135347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2914     Document Type: Article

References (37)

1. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasaltype. In: Jaffe ES, Harris NL, Stein H,Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2008. p. 285-88.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
3. Cheung MMC, Chan JK, Lau WH, et al. Early stage nasal T/NK-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182-90.
4. Chim CS,Ma SY, Au WY,et al.Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004;103:216 -21.
5. You JY Chi KH,Yang MH,et al. Radiation therapy versus chemotherapy as intal treatment for localzed nasal naturalk ller (NK)/T-celllymphoma: a s ngle nst tute survey nTa wan. Ann Oncol2004;15:618-25.
6. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-9.
7. Aviles A, Diaz NR,NeriN,et al.Angiocentric nasal T/naturalkiller celllymphoma: a single center study of prognostic factors in 108 patients. Clin Lab Haematol 2000;22:215-20.
8. Li CC,Tien HF,Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell orT-cell lymphoma. Cancer 2004;100: 366-75.
9. Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402-8.
10. Lee J, Kim WS, Park YH, et al. Nasal-type NK/Tcell lymphoma: clinical features and treatment outcome. Br J Caner 2005;92:1226-30.
11. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612-8.
12. Kim TM, ParkYH, Lee SY, et al. Local tumor invasive-ness is more predictive of survivalthan international prognostic index in stage IE/IIE extranodal NK/Tcel lymphoma, nasal type. Blood 2005;106:3785-90.
13. Lim ST, Hee SW, Quek R, et al. Comparative analysis of extra-nodalNK/T-cellymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol2008; 80:55-60.
14. Huang MJ, JiangY, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodi-gestive tract. Int J Radiat Oncol Biol Phys 2008;70: 166-74.
15. Ma HH, Zhang HY, Qian LT, et al. Prognostic factors and long term treatment outcome of 71 cases of nasal NK/Tcell lymphoma. Chin J Radiat Oncol 2008;17:7-10.
16. Li YX, Coucke PA, Li JY, et al. Primary non-Hodg-kin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998;83: 449-56.
17. Na II, Kang HJ, ParkYH, et al. Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia. Eur J Haematol 2007; 79:1-7.
18. LiYX,Fang H,Liu QF,et al.Clinical features and treatment outcome of nasal-type NK/T-cell lympho-ma of Waldeyer ring. Blood 2008;112:3057-64.
19. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodalNK/T-ce llymphoma, nasal type. Ann Oncol 2007;18:1382-7.
20. Kim TM, Lee SY,Jeon YK,et al.Clinical heterogene-ity of extranodal NK/T-cellymphoma, nasaltype: a nationalsurvey of the Korean Cancer Study Group. Ann Oncol 2008;19:1477-84.
21. CheungMMC,ChanJK,LauWH,etal.Primarynon- Hodgkin'slymphomaofthenoseandnasopharynx:clin- ical features, tumor immunophenotype, and treatment outcomein113 patients. J Clin Oncol 1998;16:70-7.
22. Shim SJ,YangWI, Shin E, et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007;67:31-8.
23. MillerTP,Dahlberg S, CassadyJR,et al. Chemothera-py alone compared with chemotherapy plus radiothera-py for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med1998;339:21-6.
24. Horning SH,WellerE, Kim KM,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22:3032-8.
25. GavrilovicIT, HormigoA,YahalomJ, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24:4570-4.
26. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes ofa study by the In-ternational Extranodal Lymphoma Study Group. Ann Oncol 2008;19:233-41.
27. Smith BD, Glusac EJ, McNiffJM, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004;22:634-9.
28. Shipp MA, Harrington DP, Anderson JR, et al. A predictive modelfor aggressive non-Hodgkin's lym-phoma. N Engl J Med 1993;329:987-94.
29. Pagano L, Gallamini A,Trape G, et al. NK/T-cell lym-phomas 'nasaltype': an Italian multicentric retrospective survey. Ann Oncol2006;17:794-800.
30. KimSJ,KimBS,Choi CW,etal.Treatmentoutcomeof front-line systemic chemotherapy for localized extrano-dal NK/Tcelllymphoma in nasaland upper aerodiges-tive tract. Leuk Lymphoma 2006;47:1265-73.
31. +, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001;19: 2179-88.
32. + hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15: 1097-108.
33. Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001;61:261-9.
34. Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentricT-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005;35:1-5.
35. Chan JK, Sin VC,Wong KF, et al. Nonnasal lympho-ma expressing the natural killer cell marker CD56: a clinicopahtologic study of 49 cases of an uncommon aggressive neoplasm. Blood1997;89:4501-13.
36. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in na-sal NK/T-celllymphoma: results ofa western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes del'Adulte (GELA) trials. Blood 2007;109:2183-9.
37. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.